Produto adicionado correctamente ao carrinho.

discount label
H-KASEKIFYV-OH
Ver 3D

Biosynth logo

H-KASEKIFYV-OH

Ref. 3D-PP45190

1mg
217,00 €
10mg
253,00 €
100mg
455,00 €
Entrega estimada em Estados Unidos, Sexta-feira 27 de Dezembro de 2024

Informação sobre produto

Nome:
H-KASEKIFYV-OH
Sinónimos:
  • NH2-Lys-Ala-Ser-Glu-Lys-Ile-Phe-Tyr-Val-OH
Descrição:

Peptide H-KASEKIFYV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-KASEKIFYV-OH include the following: The use of positional scanning synthetic combinatorial libraries (PS-SCL) to study T Lympohcyte specificity and degeneracy V Rubio-Godoy - 2002 - core.ac.ukhttps://core.ac.uk/download/pdf/18168125.pdf Combinatorial peptide library-based identification of peptide ligands for tumor-reactive cytolytic T lymphocytes of unknown specificity V Rubio-Godoy, M Ayyoub, V Dutoit - European journal of , 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/1521-4141(200208)32:8%3C2292::AID-IMMU2292%3E3.0.CO;2-K Proteasome-Assisted Identification of TRCTLI Metastatic - J Immunol, 2002 - researchgate.nethttps://www.researchgate.net/profile/Danila-Valmori-2/publication/11535787_Proteasome-Assisted_Identification_of_a_SSX-2-Derived_Epitope_Recognized_by_Tumor-Reactive_CTL_Infiltrating_Metastatic_Melanoma/links/5f168594a6fdcc3ed71b36c7/Proteasome-Assisted-Identification-of-a-SSX-2-Derived-Epitope-Recognized-by-Tumor-Reactive-CTL-Infiltrating-Metastatic-Melanoma.pdf Novel TCR-like CAR-T cells targeting an HLA∗ 0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia S Raskin, S Van Pelt, K Toner , PB Balakrishnan - Therapy-Methods & , 2021 - cell.comhttps://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(21)00146-7?elqTrackId=ae3d3c18d29343bda912fab5bc7c9424 Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA S Kreiter , T Konrad, M Sester , C Huber, aca– Tureci - Cancer immunology , 2007 - Springerhttps://link.springer.com/article/10.1007/s00262-007-0302-7 Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals S Kreiter , A Selmi, M Diken , M Sebastian - The Journal of , 2008 - journals.aai.orghttps://journals.aai.org/jimmunol/article/180/1/309/78384 Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma M Ayyoub, S Stevanovic, U Sahin - The Journal of , 2002 - journals.aai.orghttps://journals.aai.org/jimmunol/article/168/4/1717/34774 Defective Interferon Gamma Production by Tumor-Specific CD8+ T Cells Is Associated With 5'Methylcytosine-Guanine Hypermethylation of Interferon Gamma M Abd Hamid, X Yao, C Waugh - Frontiers in , 2020 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2020.00310/full Multivalent immunity targeting tumor-associated antigens by intra-lymph node DNA-prime, peptide-boost vaccination KA Smith, Z Qiu, R Wong, VL Tam, BL Tam - Cancer Gene , 2011 - nature.comhttps://www.nature.com/articles/cgt201045 227. Efficient Eradication of Castration-Resistant Human Prostate Cancers by Inactivated Sendai Virus Particle K Hatano, Y Kawaguchi, Y Miyamoto, N Nonomura - Molecular Therapy, 2011 - cell.comhttps://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)36800-9 SSX expression in gynecological cancers and antibody response in patients K Hasegawa, F Koizumi, Y Noguchi, A Hongo - Cancer Immunity, 2004 - AACRhttps://aacrjournals.org/cancerimmun/article-abstract/4/1/16/472242 Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients J Laurent, DE Speiser , V Appay, C Touvrey - Journal of , 2010 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2010/09000/Impact_of_3_Different_Short_term_Chemotherapy.00009.aspx Cancer-associated antigens and their clinical potential for immunotherapy J Ganapathy , VV Prabhu - Malaya Journal of Biosciences. Journal , 2016 - researchgate.nethttps://www.researchgate.net/profile/Vinod-Prabhu-3/publication/312088973_Cancer-associated_antigens_and_their_clinical_potential_for_immunotherapy/links/586ee12f08ae8fce491ca37a/Cancer-associated-antigens-and-their-clinical-potential-for-immunotherapy.pdf Peptides for vaccine development IW Hamley - ACS Applied Bio Materials, 2022 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acsabm.1c01238 Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells HA Smith , DG McNeel - Journal of Immunotherapy, 2011 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2011/10000/Vaccines_Targeting_the_Cancer_testis_Antigen_SSX_2.1.aspx The SSX family of cancer-testis antigens as target proteins for tumor therapy HA Smith , DG McNeel - Journal of Immunology Research, 2010 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/full/10.1155/2010/150591 Evaluating the SSX Family of Cancer-Testis Antigens as Immunological Targets for the Treatment of Prostate Cancer H Smith - 1912 - asset.library.wisc.eduhttps://asset.library.wisc.edu/1711.dl/3Q3NIGU7BLH5S84/R/file-6c18f.pdf Development of a T cell receptor targeting an HLA-A* 0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer D Abate-Daga, DE Speiser , N Chinnasamy, Z Zheng - PloS one, 2014 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0093321

Aviso:
Os nossos productos estão destinados exclusivamente para uso em laboratório. Para qualquer outra aplicação, por favor entre em contacto.
Marca:
Biosynth
Armazenamento a longo prazo:
Notas:

Propriedades químicas

MDL:
Ponto de fusão:
Ponto de ebulição:
Ponto de inflamação:
Densidade:
Concentração:
EINECS:
Merck:
Código HS:

Informação sobre riscos

Número ONU:
EQ:
Classe:
Frases H:
Frases P:
Proibido de voar:
Informação sobre riscos:
Grupo de Embalagem:
LQ:

Consulta técnica sobre: 3D-PP45190 H-KASEKIFYV-OH

Por favor, utilize o carrinho para solicitar um orçamento ou uma encomenda

Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.

* Campos obrigatórios
Bem-vindo à CymitQuimica!Usamos cookies para melhorar sua visita. Não incluímos publicidade.

Consulte a nossa Política de Cookies para mais detalhes ou ajuste suas preferências em "Configurar".